Studies outcomes of microwave ablation for small kidney and liver tumors
Collects data on microwave ablation treatment in adults with kidney or liver tumors.
Plain-language title generated from the registry record
Registry title: Microwave Ablation for Treatment of Small Renal Tumors and Primary and Secondary Liver Neoplasms
Key facts
- Where
- Milan, ItalySee the site
Where in Italy
- IRCCS Ospedale San RaffaeleMilan, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Francesco De Cobelli
- Trial code
- NCT03981497
- Record updated
- 23 September 2026
- Original description
The goal of this observational study is to collect data on efficacy and safety of microwave ablation (MWA) used to treat subjects with primary and secondary liver malignancies and renal malignancies. The main question it aims to evaluate the short, medium and long-term clinical course of patients treated with MWA.Read full original descriptionShow less
Retrospective and Perspective Analysis of Short, Medium and Long Term Clinical Performance of Patients Undergoing MicrowaveThermal Ablation for Treatment of Small Renal Tumors and Primary and Secondary Liver Neoplasms
The goal of this observational study is to collect data on efficacy and safety of microwave ablation (MWA) used to treat subjects with primary and secondary liver malignancies and renal malignancies. The main question it aims to evaluate the short, medium and long-term clinical course of patients treated with MWA.
Participants will not alter their normal clinical and therapeutic practice, due to the observational nature of the study, and all data regarding microwave treatments will be collected (including demographic data). follow their normal clinical and therapeutic path
Inclusion: > 18 years with primary or secondary liver tumors or small kidney tumors that are not candidates for surgery or cannot be radically resected by surgery alone; Primary liver cancer: up to three liver nodules ≤ 3 cm; Secondary hepatic tumours: up to nodules ≤ 3 cm provided that the objective is complete hepatic clearance Renal tumours: single or multiple (von Hippel Lindau syndrome), < 4 cm.
Exclusion: Extended extrahepatic or extrarenal disease; pregnant women; non-manageable coagulopathies; for liver ablation: presence of bilio-digestive anastomosis.